| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
427 |
370 |
$32K |
| 90960 |
End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits |
157 |
154 |
$28K |
| 90961 |
|
168 |
165 |
$24K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
61 |
53 |
$3K |
| 99223 |
Prolong inpt eval add15 m |
13 |
12 |
$2K |
| M1171 |
Patient received at least one td vaccine or one tdap vaccine between nine years prior to the encounter and the end of the measurement period |
468 |
368 |
$0.00 |
| M1177 |
Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period |
457 |
359 |
$0.00 |
| M1200 |
Ace inhibitor (ace-i) or arb therapy prescribed during the measurement period |
463 |
366 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
287 |
229 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
287 |
229 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
20 |
12 |
$0.00 |
| 1036F |
|
20 |
12 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
524 |
411 |
$0.00 |
| M1189 |
Documentation of a kidney health evaluation defined by an estimated glomerular filtration rate (egfr) and urine albumin-creatinine ratio (uacr) performed |
381 |
297 |
$0.00 |
| M1168 |
Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period |
473 |
372 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
536 |
416 |
$0.00 |
| M1174 |
Patient received at least two doses of the herpes zoster recombinant vaccine (at least 28 days apart) on october 20, 2017, through the end of the measurement period |
470 |
369 |
$0.00 |
| G0030 |
Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user |
237 |
189 |
$0.00 |